Skip to content

Robotic Versus Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms

Comparison Between Robotic and Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05259384
Enrollment
120
Registered
2022-02-28
Start date
2021-04-17
Completion date
2024-10-31
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Neoplasm

Brief summary

Pancreatic cystic neoplasm (PCN) is a type of neoplastic lesion formed by the proliferation of pancreatic duct or acinar epithelial cells and retention of pancreatic secretions. The tumor can be located in the head and neck of the pancreas or the body and tail of the pancreas. Conventionally, open pancreaticoduodenectomy or open distal pancreatectomy was performed for patients with PCN locates either at the head or tail. In the ear of minimally invasive pancreatic surgery, when compared with open surgery, laparoscopic technology or Da Vinci robotic technology can avoid some open procedures limitations. Here we design this prospective randomized clinical trial to compare robotic surgery to laparoscopic surgery for the treatment of PCN and verify the safety and feasibility of both two minimally invasive procedures.

Detailed description

Background: Pancreatic cystic neoplasm (PCN) is a type of neoplastic lesion formed by the proliferation of pancreatic duct or acinar epithelial cells and retention of pancreatic secretions. Its heterogeneity is large, which can be benign, borderline, and poor differentiation and even evolve into pancreatic cancer. The tumor can be located in the head and neck of the pancreas or the body and tail of the pancreas. Some patients may be accompanied by recurrent pancreatitis, abdominal pain, nausea, vomiting, jaundice, and other gastrointestinal symptoms, usually with the help of abdominal ultrasound and endoscopy, ERCP, CT, nuclear magnetic, or MRCP imaging The examination can diagnose the disease. For PCN patients with large tumors, risk of malignant transformation, and accompanying symptoms that affect the quality of life, surgery is an effective treatment. Based on the conventional routine treatment, open pancreaticoduodenectomy or open distal pancreatectomy was performed for patients with PCN locates either at the head or tail. After more than 20 years of development, minimally invasive pancreatic surgery technology can be divided into two categories: laparoscopic technology and Da Vinci robotic technology. In general, compared with open surgery, minimally invasive pancreatic surgery technology can avoid some open procedures limitations, reduce the loss of intraoperative body fluid and its impact on the internal environment, and avoid excessive disturbance to other abdominal organs. It also helps reduce the pain of patients and shorten the length of hospital stay. Because most PCNs are benign or borderline tumors, such patients are eligible for minimally invasive pancreatic surgery. Aim and Hypothesis: Here we design this prospective randomized clinical trial to compare robotic surgery to laparoscopic surgery for the treatment of PCN and verify the safety and feasibility of both two minimally invasive procedures. We conduct a single-center prospective randomized clinical trial to compare the outcomes of different minimally invasive techniques.

Interventions

The Intervention of MIPD-ROB group

The Intervention of MIPD-LAP group

PROCEDURERobotic Distal Pancreatectomy

The Intervention of MIDP-ROB group

The Intervention of MIDP-LAP group

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The enrolled candidates will be split into two subgroups(PD group or DP group) based on the location of their neoplasms. Every subgroups will be divided into two parallel groups by the randomization of intervention plan(lap surgery or robotic surgery)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 18 years old or older; 2. Diagnosed as PCN; 3. Patients with head or neck PCNs are eligible for minimal invasive PD, or patients with distal PCNs are eligible for minimal invasive DP.

Exclusion criteria

1. Not a PCN base on the sample's pathology; 2. Procedure change from MIDP/MIPD to others during the operation; 3. ASA more than 4; 4. Patients or families deny certain treatment.

Design outcomes

Primary

MeasureTime frameDescription
Complication Rateup to 90 daysThe rate of frequency of Clavein-Dindo Grade II-IV complication

Secondary

MeasureTime frameDescription
VAS scoreup to 90 dayspatients complain of pain after surgery, 0-10, 10 means the greatest pain
Grade B and C pancreatic fistulaup to 90 daysThe frequency of grade B or C pancreatic fistula
QOL scoreup to 90 daysQuality of life after surgery, greater means higher life satisfaction
Postoperative length of stayduring the treatmentThe mean of postoperative length of stay
90-day death rateup to 90 daysThe rate of death within 90 days after surgery
The rate of spleen-preservationup to 90 daysFor DP groups, the rate of spleen being preserved
Expenseduring the treatmentThe amount of treatment expense and certain procedure expense

Countries

China

Contacts

Primary ContactHanyu Zhang, M.D.
medzhy5813@126.com01069152600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026